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Crohn’s Disease and Ulcerative Colitis, the major forms of inﬂammatory bowel diseases (IBDs) in humans, have been traditionally
associated with exaggerated and poorly controlled T helper (Th) type 1 or Th2 cell response, respectively. More recent studies
have, however, shown that IBDs are also characterized by a sustained production of cytokines made by a distinct lineage of Th
cells, termed Th17 cells. The demonstration that Th17-related cytokines cause pathology in many organs, including the gut, and
that expansion and maintenance of Th17 cell responses require the activity of IL-23, a cytokine made in excess in the gut of IBD
patientshascontributedtoelucidatenewpathwaysofintestinaltissuedamageaswellastodesignnewtherapeuticstrategies.Inthis
review,wediscusstheavailabledatasupportingtheroleoftheIL-23/Th17axisinthemodulationofintestinaltissueinﬂammation.
Copyright © 2009 Ivan Monteleone et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the
major forms of inﬂammatory bowel diseases (IBDs) in
humans. The etiology of IBD is still unknown, but evidence
has been accumulated to indicate that environmental and
genetic factors contribute to promote an immunopathologic
process leading to chronic inﬂammation [1]. Studies of
experimental models of IBD and clinical observations also
suggest that CD4+ T-cells play a major role in initiating and
shaping the pathologic response in IBD. Consistently, T-cell-
directed therapies have been employed with some clinical
success in IBD patients [1–3].
The ability of CD4+ T-cells to alter the magnitude and
outcome of the intestinal tissue-damaging inﬂammatory
responses is mostly dependent on the production of distinct
proﬁles of cytokines [4]. Traditionally, CD lesion has been
associated with a predominant activation of T helper type
1 (Th1)-lymphocytes that produce large quantities of inter-
feron (IFN)-γ under the stimulus of interleukin (IL)-12 [5–
7]. By contrast, the UC lesion was believed to be driven by
Th2-cytokines, such as IL-4 and IL-13 [8, 9]. More recently,
studies from several laboratories had led to the identiﬁcation
of more complex networks of cytokine interactions in IBD
tissue, thus shedding light into the role of a distinct subset
of Th cells, namely, Th17 cells, in the pathogenesis of colitis
[10–13]. In this paper, we will review the available data
supporting the involvement of Th17 cells in the modulation
of gut inﬂammation.
2. Th17 CellInduction andFunctions
Th17 cells have derived the name by their ability to produce
IL-17, also termed IL-17A. Additional cytokines produced
by Th17 cells include IL-17F, IL-21, IL-22, TNF-α,a n dI L - 6
[14].WhileTh1andTh2celldiﬀerentiationsdependontheir
respective eﬀector cytokines (i.e., IFN-γ and IL-4, resp.),
induction of Th17 cells does not require IL-17A [14]. By
contrast, Th17 cell development requires the activity of the
transcription factors retinoic acid-related orphan receptor
(ROR) γta n dR O R α, and RUNX1, and is driven by TGF-
β1[ 14–16]. Th1 and Th2-related cytokines inhibit Th17 cell
diﬀerentiation, while IL-17 is not able to suppress Th1 and
Th2 cells or does so very weakly [17]. Therefore, suppression
of IFN-γ and IL-4 represents a way by which TGF-β1c o u l d
promote Th17 cell diﬀerentiation, even though TGF-β1-
driven Th17 cell development can also occur in the absence
of IFN-γ and IL-4 [18, 19]. The eﬀects of TGF-β1o n
Th17 cell diﬀerentiation are concentration dependent; low
doses induce Th17 cells, while high doses inhibit Th17 cell
development and promote regulatory T-cells (Tregs) [20].2 Mediators of Inﬂammation
Importantly, Tregs can convert into inﬂammatory Th17 cells
in the presence of inﬂammatory cytokines such as IL-6 [21].
Since Th17 cells appear to be resistant to the Tregs-mediated
immunosuppression [22], it is likely that during chronic
inﬂammatory processes, such as IBD, Tregs may augment
rather than suppressing Th17-mediated immune responses.
Th17 diﬀerentiation can be induced by IL-21 in IL-6-
deﬁcient mice [23]. These observations and the demon-
stration that IL-21 is made by T-cells in response to IL-
6 clearly indicate that IL-21 acts downstream of IL-6 in
Th17 cell generation. Importantly, IL-21 stimulates Th17
cells to produce IL-21, thus triggering an autocrine loop
that ampliﬁes Th17 cell responses [24]. IL-21 enhances the
expression of IL-23 receptor (IL-23R) in Th17 cells, through
a process that is dependent on Stat3 and RORγt, making
these cells responsive to IL-23 [25]. Since IL-23 facilitates the
expansion and/or stabilization of the Th17 phenotype, these
data suggest a mechanism by which IL-21 could contribute
to amplify Th17-cell responses. Th17 cell responses are also
sustained by IL-1 [26].
Th17 cell-derived cytokines are supposed to play an
important role in the protection of the host against various
bacteria and fungi, particularly at mucosal surfaces, given
their ability to enhance the recruitment and facilitate the
activation of neutrophils and stimulate the production of
defensins by epithelial cells [27, 28]. In line with this it was
shownthatTh17cellsareconstitutivelypresentinthehuman
and mouse intestinal mucosa [29] .S t u d i e si nm i c eh a v ea l s o
shown that, in the gut, commensal bacteria drive the diﬀer-
entiation of Th17 cellsthrougha mechanism whichis strictly
dependent on the production of adenosine 5 -triphosphate
(ATP) [29]. Additionally, it was shown that stimulation of
dendritic cells with toll-like receptor (TLR) ligands induces
synthesis of cytokines that promoted diﬀerentiation of IL-
17 producing CD4+ T-cells [30]. Similarly, stimulation of
dendritic cells with bacterial-derived ligands for NOD-2
results in enhanced IL-17 production by human memory T-
cells,throughanIL-1andIL-23-dependentmechanism[31].
It has been also demonstrated that Th17 cells can be induced
independent of TLR activation. For instance, engagement of
the C-type lectin dectin-1 with curdlan stimulates dendritic
cells to secrete IL-6, TNF-α, and IL-23 thus promoting the
diﬀerentiationofTh17cells[32].IL-23isabsolutelyrequired
for providing Th17 cells a pathogenic phenotype. In fact,
in the absence of IL-23, Th17 cells may have regulatory
functions that correlate, in part, with their ability to produce
IL-10 [33, 34].
Th17-related cytokines can trigger several inﬂammatory
pathways due to their ability to enhance the synthesis of
inﬂammatory cytokines (e.g., IL-1, IL-6, TNF-α,G M - C S F ) ,
chemokines (e.g., IL-8, CXCL1, CXCL8, monocyte chemoat-
tractant protein-1, monocyte-inhibitor protein (MIP)-3α),
cyclooxygenase-2, and tissue-degrading matrix metallopro-
teinases (MMPs) [27, 35].
3. Expressionof Th17 Cytokines in Human IBD
In 2003, Fujino et al. showed an increased number of IL-
17-producing cells in the inﬂamed gut of patients with CD
and patients with UC in comparison to normal and disease
controls [12]. By immunohistochemistry, it was shown that,
in active UC, IL-17-expressing cells were located mainly
withinthelaminapropria,whileinactiveCD,thesecellswere
scatteredthroughoutthesubmucosaandmuscularispropria.
Major sources of IL-17 were CD3+ T-cells and CD68+
cells. In line with this, it was shown that RNA transcripts
for IL-17A and IL-17F were upregulated in the inﬂamed
mucosa of UC patients and CD patients [12, 36]. More
recently Annuziato et al. demonstrated that the number of
IL-17-producing T-cells is higher in CD than in normal
gut mucosa, and that some of these cells produce also
IFN-γ [37]. Stimulation of these cells with IL-12-enhanced
expression of Th1-related markers (i.e., T-bet and IFN-γ)
and downregulated RORγt and IL-17, thus indicating that
IL-17-secreting T-cells can be induced to diﬀerentiate in
fullypolarized Th1 cells [37]. There is also evidence that
treatment of intestinal lymphocytes with IL-23 enhances
either IL-17A or IFN-γ in UC or CD, respectively [38].
TheinﬂamedmucosaofIBDpatientscontainshighlevels
of other Th17-related cytokines. Indeed we have previously
shown that in both CD and UC tissues there is enhanced
production of IL-21, a cytokine that is capable of expanding
the ongoing Th1 cell response in CD [39], stimulating
gut ﬁbroblasts to secrete MMPs [40], and inducing colonic
epithelial cells to produce the chemokine MIP-3α [41]. IL-
22 is also highly expressed in mucosal samples of patients
with active CD and to a lesser degree of patients with UC
[42]. Like other Th17 members, IL-22 stimulates colonic
ﬁbroblasts to make inﬂammatory cytokines (e.g., IL-6, IL-
8, IL-11, and leukemia inhibitory factor), chemokines, and
MMPs [42]. Moreover, IL-22 enhances the expression of
TNF-α,I L - 8 ,a n dβ-defensin [43].
Upregulation of Th17-related cytokines does not how-
ever represent a speciﬁc hallmark of IBD, as increased levels
ofIL-17AandotherTh17-markershavebeenseeninpatients
with rheumatoid arthritis, multiple sclerosis, and psoriasis
[44–46]. Moreover, studies in murine models of these
pathologiesstronglysuggestthatTh17cellsplayapivotalrole
in propagating tissue-damaging immune responses [47–49].
4. Role of Th17 Cells in the Pathogenesis of
ExperimentalColitis
By using IL-17 receptor A (IL-17RA) knockout mice, Zhang
et al. showed that IL-17 is necessary for the development of
colitis induced by intrarectal administration of trinitroben-
zenesulfonic (TNBS) acid [50]. Consistently, administration
of IL-17RA IgG1 fusion protein in mice with TNBS-colitis
signiﬁcantly attenuated colonic inﬂammation and prevented
weight loss. In this context it is however noteworthy that
IL-17RA mediates the activities of both IL-17A and IL-17F
[51], making diﬃcult to establish the exact contribution of
these cytokines in the pathogenesis of TNBS-colitis. Studies
in other models of colitis, such as the dextran sulfate sodium
(DSS)-induced colitis, showed that IL-17F deﬁciency results
in reduced colitis, whereas IL-17A-null mice develop more
severe disease [52].Mediators of Inﬂammation 3
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Figure 1: Role of Th17 cells in the modulation of intestinal inﬂammation. Th17 cells diﬀerentiate from na¨ ıve T lymphocytes under the
stimulus of TGF-β, IL-6, and IL-1, while the dendritic cells derived IL-23 and the Th17 cell-derived IL-21 contribute to maintain/expand
Th17 cell populations. Th17-derived cytokines, such as IL-17A, IL-21, and IL-22, promote the recruitment of inﬂammatory cells in the
intestinal lamina propria, due to their ability to enhance the synthesis of chemoattractants and adhesion molecules (e.g., ICAM-1) by
epithelial and endothelial cells, respectively. IL-17A, IL-21, and IL-22 stimulate ﬁbroblasts to make matrix metalloproteinases, a family
of enzymes that could contribute to the tissue damage and remodeling occurring in IBD. IL-17A and IL-22 also stimulate the synthesis
of antibacterial proteins, including defensins, by epithelial cells. DC; Dendritic cells; TGFβ; transforming growth factor-β; MMPs; matrix
metalloproteinases; ICAM-1; intercellular adhesion molecule-1.
Th17 cells seem to be involved in the pathogenesis of
colitisinducedbytransferofacecalbacterialantigen-speciﬁc
C3H/HeJBir (C3Bir) CD4 (+) T-cell line to C3H/HeSnJ
SCID mice [13] (see Figure 1). In this model, colitis asso-
ciated with enhanced production of IL-17, and adoptive
transfer of IL-17-secreting T-cells to SCID recipients resulted
in a marked gut inﬂammation, as compared to that caused
by transfer of Th1 cells. Administration of mice with
a monoclonal anti-IL-23p19 prevented and treated active
colitis, downregulated the synthesis of a broad array of
inﬂammatory cytokines and chemokines in the colon, and
promoted apoptosis of colitogenic Th17 cells. By using a
novel model of CD8+ T-cell-dependent colitis, Tajima et
al. have recently shown that a single adoptive transfer of
na¨ ıve CD8+ T-cells into syngeneic RAG-deﬁcient mice was
followed by rapid spontaneous proliferation of these cells in
the mesenteric lymph nodes and severe colitis [53]. Analysis
of cytokine-secreting CD8+ T-cells in the mesenteric lymph
nodes showed the existence of IL-17 and IFN-γ-double-
positive cells. Notably, adoptive transfer of na¨ ıve CD8+ T-
cells derived from either IL-17- or IFN-γ-knockout mice
associated with a remarkably less severe colitis, raising the
intriguing possibility that IL-17 and IFN-γ can cooperate
to cause pathology in this model of colitis. Consistent with
these ﬁndings is our demonstration that IL-21-null mice are
largely protected against the development of DSS-colitis and
TNBS-relapsing colitis [54]. This protection was associated
with a reduced colonic expression of several Th17- and
Th1-related genes. Additionally, blockade of IL-21 activity
with a speciﬁc IL-21R-fusion protein reduced intestinal
inﬂammation and Th17 response during the course of DSS
colitis [54].
TakentogethertheseﬁndingssuggestthatTh17cytokines
contribute to orchestrate the T-cell response that causes
tissue damage in the gut.
5. IL-23 andGutInﬂammation
IL-23 is a heterodimeric cytokine composed by the speciﬁc
p19 subunit and the p40 chain that is shared with IL-12
[55]. The synthesis of the p40 subunit and the functional
heterodimeric IL-23 is enhanced in the gut of CD patients
[5, 56]. In a recent study, kamada et al. showed that IL-
23 is made preferentially by a subset of mucosal cells
expressing both macrophage (i.e., CD14, CD33, CD68) and
dendritic cell markers (i.e., CD205, CD209) and present in
large numbers in CD tissue [57]. These cells induce lamina
propria mononuclear cells to make IFN-γ rather than IL-
17 production through an IL-23 and TNF-alpha-dependent4 Mediators of Inﬂammation
mechanism [57]. This substantiates further the concept that,
in CD, IL-23 may expand the ongoing Th1 cell response In
line with these data, a neutralizing p40 monoclonal antibody
has shown clinical eﬃcacy in patients with moderate and
severe CDs [58]. If the therapeutic eﬀect of this novel reagent
is due to the neutralization of IL-12 and/or IL-23 remains
to be ascertained. However, studies conducted in various
animal models of colitis would seem to indicate that IL-23 is
morepathogenicthanIL-12inthegut.Forinstance,byback-
crossing IL-10-deﬁcient mice with mice lacking IL-12p35 or
IL-23 p19, Yen et al. showed that IL-23 was essential for
manifestation of chronic intestinal inﬂammation, whereas
IL-12 was not [59]. CD4+ T-cells from IL-10/p19-knockout
mice still produced large amounts of IFN-γ, thus indicating
that Th1 responses developed normally in the absence of IL-
23, but disease manifestations required the presence of IL-
23. Moreover, administration of exogenous IL-23 in RAG
mice reconstituted with na¨ ıve CD4+ T-cells caused a more
severe colitis that was associated with enhanced production
of IL-6 and IL-17 and preventable by treatment of mice with
a blocking IL-6 or IL-17 antibody. Although in this model,
IL-6 and IL-17 were made by memory T-cells, there is no
doubt that some of the pathogenic functions of IL-23 in
the gut are mediated by non-T-cell populations. This was
ﬁrst shown by Powrie et al. who analyzed the eﬀect of an
agonistic anti-CD40 antibody in RAG mice lacking IL-23p19
or IL-12p35 [60]. Administration of anti-CD40 caused a
systemic and local inﬂammation characterized by wasting
disease, splenomegaly, increases in serum proinﬂammatory
cytokines, and colitis. It was shown that the systemic
inﬂammatory response and the elevated concentrations of
proinﬂammatory cytokines in the serum were driven by IL-
12 while the local intestinal inﬂammation and production of
IL-17intheintestinewerecontrolledbyIL-23.Morerecently,
using the T-cell transfer model of colitis, the same group
has shown that IL-17-deﬁcient T-cells are not impaired in
their ability to induce colitis in RAG mice [61]. Protection of
colitis seen in RAG mice lacking IL-23 was associated with
no decrease in the levels of IL-17, as well as lack of IL-23
did not signiﬁcantly aﬀect the relative amounts of the Th17-
speciﬁcfactorRORγtinthecolon.Consistentwiththisstudy,
Noguchi et al. showed that transfer of na¨ ıve CD4+ T-cells
prepared from IL-17-knockout mice induced severe colitis
in RAG mice [62]. Together, these data indicate that Th17
cell responses are not speciﬁcally impaired in the intestine of
IL-23-deﬁcient mice and that IL-23-mediated colitis is not
strictly dependent on IL-17 production.
A more detailed analysis of the mechanisms underling
the IL-23-dependent pathologies revealed that IL-23 can
facilitate colitis not only via direct eﬀects on inﬂammatory
mediators but also indirectly by counteracting regulatory
mechanisms. Indeed, protection of colitis seen after transfer
of na¨ ıve T-cells to RAG mice lacking IL-23 was associated
with an increase in the frequency of Foxp3-expressing T reg-
ulatory cells in the intestine [61]. Upon na¨ ıve T-cell transfer,
administration of mice with either an antagonistic IL-10R
antibody or a blocking TGF-β antibody increased colonic
inﬂammation compared to untreated controls. Moreover
na¨ ıve T-cells isolated from transgenic mice expressing a
dominant-negative form of TGF-β receptor II and unable
to respond to TGF-β induced signiﬁcant colitis when trans-
ferred to IL-23-deﬁcient RAG mice [61]. High levels of IFN-
γ, but not IL-17, were seen in colitic mice, thus suggesting
that IFN-γ might drive the chronic intestinal inﬂammation
in this setting. Notably, transfer of Foxp3-deﬁcient T-cells
to IL-23-deﬁcient RAG mice caused severe colitis, indicating
that IL-23 is not essential to the pathogenesis of intestinal
inﬂammation,ifcounterregulatorymechanismsaredefective
or absent [61]. These later ﬁndings well ﬁt with the notion
that the requirement of IL-23 for the initiation and progress
of gut inﬂammation varies depending on the model. In
fact, acute colitis induced by TNBS is driven by IL-12 and
negatively regulated by IL-23 [63].
6. Conclusions
The recent discovery that IL-23 and Th17 cells play a major
roleinthedevelopmentofchronicintestinalinﬂammationin
mouse models of IBD together with the identiﬁcation of IL-
23R gene polymorphisms that inﬂuence IBD susceptibility
[64] has provided a new picture of the way the local immune
response can promote intestinal tissue damage. These new
data suggest that, at least in theory, the IL-23/Th17 axis
could be a promising target for suppressing inﬂammation in
IBD. This is in line with the demonstration that blockade
of cytokines that positively regulate Th17 cell polarization
can dampen colitis. For instance, a monoclonal antibody
targeting IL-6R has been successfully used in patients with
active CD [65]. Both in vitro and in vivo data showed
that anti-IL-6 treatment enhanced mucosal T-cell apoptosis.
However, given the critical role of IL-6 in the diﬀerentiation
of Th17 cells [66], it is tempting to speculate that the
beneﬁcial eﬀect of anti-IL-6R may in part rely on the control
of Th17 cell responses. Nonetheless, some important issues
remain to be resolved. For example, emerging evidence
suggests that Th17 cell biological eﬀects are strictly context-
dependent, and that Th17 cells can promote either protective
or pathogenic responses depending on additional factors
present within the mucosal milieu. So, further experimen-
tation is needed to identify such factors. Mechanisms that
triggerandregulateTh17cellresponseinhumanIBDremain
to be elucidated. Similarly it is unknown whether and how
these cells interact in vivo with other regulatory and eﬀector
mucosal T-cell subsets. It is also unclear whether the vari-
ous Th17 cytokines make qualititatively and quantitatively
diﬀerent contributions to the initiation and progress of gut
inﬂammation or whether they are redundant in their ability
to modulate speciﬁc inﬂammatory pathways. It remains also
to be clariﬁed why mice lacking IL-23 or speciﬁc Th17-
related genes are diﬀerently susceptible to speciﬁc forms of
experimental colitis. As pointed out above, Th17-cytokines
are constitutively produced in the normal human and mouse
gut, raising the possibility that these molecules may be
involved in the maintenance of immunological homeostasis
and/or in the control of speciﬁc inﬂammatory pathways.
If this is the case, blocking Th17-cytokines could have
deleterious rather than beneﬁcial eﬀects for the host.Mediators of Inﬂammation 5
Finally, experimental studies are still necessary to ascer-
tain whether prolonged treatment with biological com-
pounds that interfere with Th17 cell functions can enhance
the risk of infections and cancer, given that Th17 cytokines
mediate host-defensive mechanisms to bacteria and fungi
and exert antitumor activity.
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